Penile Traction Devices (Extenders) (Device)

Evidence: Moderate — Downgraded from "Strong" per devil's advocate: studies are small (n=15-110), some are in Peyronie's patients (not cosmetic), and compliance is a major confound.

Mechanism: Claimed: sustained mechanical traction induces cellular proliferation (cytokinesis) via the Ilizarov principle applied to soft tissue. Actual: mechanotransduction is plausible based on in vitro studies showing collagenase upregulation and metalloproteinase-8 expression under strain (Ralph 2013), but no human histological confirmation of permanent tissue growth in healthy penile tissue.

Gains: Flaccid: +0.9-1.7cm. Erect: +0-1.7cm (highly variable, often not statistically significant). 2025 review: 1.5-2.3cm with high adherence. | Time: 30-90 min/day (modern) or 4-8 h/day (older protocols) for 3-6+ months. Compliance is the #1 limiting factor. | Cost: $100-$500

Risks: Discomfort, skin irritation, temporary numbness, reduced sensitivity if overused. Rare Peyronie's exacerbation. Trost 2019 reported no significant adverse events with RestoreX.

Verdict: Best NON-SURGICAL option, but evidence is more modest than often claimed. Most robust data is for Peyronie's disease (recovering lost length), not cosmetic augmentation in healthy men. Gains are measured in millimeters to low centimeters, not inches. Requires months of daily commitment. Modern short-duration protocols (RestoreX, 30-90 min) show similar results to exhausting 4-8h/day regimens.

Penuma Silicone Implant (Surgery)

Evidence: Moderate — Downgraded: mostly manufacturer-supported studies, limited independent replication, poor long-term follow-up. True complication rates may be higher than reported.

Mechanism: FDA-cleared subcutaneous silicone sleeve surgically placed around the penile shaft. Adds permanent girth and modest flaccid length. Does not modify the corpora cavernosa.

Gains: Length: +2.5-3.8cm (flaccid). Girth: +3.1-3.4cm. Penoscrotal approach has best outcomes. | Time: Single surgery (2-3h) + 4-6 week recovery. No sex for 6 weeks post-op. | Cost: $13,000-$18,000

Risks: Seroma (1-12%), erosion (3.6%), infection (0.6%), revision (2-13%), removal (6-21%). Migration (rare). Penoscrotal approach significantly safer than infrapubic.

Verdict: Only FDA-cleared cosmetic penile implant. Largest absolute gains available. BUT: manufacturer-supported data, limited independent follow-up, significant surgical risks, expensive. Penoscrotal approach strongly preferred. Not for men with PDD (surgery worsens dysmorphia).

Hyaluronic Acid Filler Injection (Injectable)

Evidence: Moderate — Growing evidence base but TEMPORARY (12-24 months), NOT FDA-approved for penile use.

Mechanism: Cross-linked hyaluronic acid injected subcutaneously into the penile shaft for girth enhancement. Biodegradable over 12-24 months. Can be dissolved with hyaluronidase if problems arise.

Gains: Girth: +1.5-3.0cm per treatment. Multiple treatments yield greater gains (+2.95cm with 4+ sessions). | Time: 30-60 min outpatient procedure. Repeat every 12-24 months. | Cost: $3,000-$8,000 per session

Risks: Subcutaneous bleeding, nodules, infection, granuloma (~0.6%, treatable). NOT FDA-approved for this use. Avoid non-cross-linked HA (migrates).

Verdict: Most promising non-surgical GIRTH option. Temporary but reversible (hyaluronidase can dissolve it). Growing safety data (retrospective n≈500 looks reassuring). NOT FDA-approved. Must be performed by experienced injector. Repeat sessions needed.

Vacuum Erection Devices (Pumps) (Device)

Evidence: None (for permanent size) — Strong evidence for ED treatment and post-surgical rehab. ZERO peer-reviewed evidence for permanent enlargement.

Mechanism: Negative pressure draws blood into penis, causing temporary engorgement beyond normal capacity. Creates edema (fluid accumulation) — NOT tissue growth. Medical-grade VEDs validated for ED treatment.

Gains: TEMPORARY: +0.5-1.5cm during/shortly after use (edema, not growth). PERMANENT: zero evidence. | Time: 15-20 min sessions. 3-5x per week for ED rehab. | Cost: $30-$350 (consumer) / $150-$500 medical-grade (often insurance-covered)

Risks: Petechiae (blood spots), edema, bruising, hematoma. Aggressive/prolonged use can trigger Peyronie's. Constriction ring: max 30 min.

Verdict: Legitimate, FDA-cleared treatment for ED. Useful for post-surgical rehab. But for SIZE: temporary puffiness, not permanent growth. The "gains" disappear within hours. Marketing claims of permanent enlargement are unsupported by any peer-reviewed science.

Suspensory Ligament Release (Surgery)

Evidence: Weak — Declining popularity. Poor satisfaction. Many urologists no longer recommend.

Mechanism: Surgical division of the fundiform and suspensory ligaments that anchor the penis to the pubic symphysis. Allows more internal shaft to extend externally. Often combined with V-Y plasty skin advancement.

Gains: Flaccid: +1-3cm. Erect: NONE (often worse — loss of erection angle). | Time: Surgery + 6-8 week recovery + mandatory post-op stretching (months). | Cost: $5,000-$15,000

Risks: Loss of erection angle (penis points downward), penile instability during intercourse, scarring, wound infection, SHORTENING if post-op stretching skipped. 35-50% satisfaction.

Verdict: Declining popularity for good reason. Gains are flaccid-only, with loss of erection angle. High dissatisfaction (up to 70%). Many urologists now advise against it. Post-op stretching is critical but painful.

P-Shot (PRP Therapy) (Injectable)

Evidence: Weak — Heavily marketed despite failed placebo-controlled replication. Cleveland Clinic says "no good evidence."

Mechanism: Platelet-rich plasma (autologous blood concentrate) injected into corpus cavernosum. Claimed to stimulate growth factors, neovascularization, and tissue regeneration.

Gains: UNPROVEN. The one positive study was uncontrolled; the controlled study failed. | Time: 30 min procedure. May need 3-6 sessions. | Cost: $1,500-$3,000 per session

Risks: Pain, bruising, infection (rare). Generally physically safe, but financially predatory.

Verdict: Classic case of marketing outrunning evidence. One small uncontrolled study showed gains; the proper controlled study failed. Yet clinics charge thousands per session. Evidence does NOT support use for enlargement.

Manual Exercises (Jelqing) (Exercise)

Evidence: None — ZERO peer-reviewed clinical studies. All "evidence" is anonymous internet forum posts with severe survivorship bias.

Mechanism: Claimed: "milking" motion forces blood through semi-erect penis, creating micro-tears that heal larger. Actual: no physiological basis. The penis is NOT a muscle and doesn't hypertrophy from exercise. Claimed "ancient Arabic" origins are unverifiable.

Gains: UNPROVEN. No credible evidence of any permanent gains. | Time: 20-30 min daily (per forum protocols) | Cost: Free

Risks: Peyronie's disease (plaque formation from repeated trauma), vascular damage, nerve damage, bruising, lymph blockage, decreased erection quality. Risk increases with intensity.

Verdict: Zero scientific evidence. Real risk of permanent injury (documented in case reports). Not recommended by any medical organization. The "ancient technique" narrative is marketing fiction. If something sounds too good to be true and free, it probably is.

Li-ESWT (Shockwave Therapy) (Therapy)

Evidence: Moderate (ED only) — Good evidence for ERECTION quality. ZERO evidence for SIZE increase. Often misleadingly marketed.

Mechanism: Low-intensity extracorporeal shock waves stimulate neovascularization (new blood vessel growth) and nerve regeneration in penile tissue. Does NOT cause tissue expansion or elongation.

Gains: Improved erection quality: yes. Size increase: NONE. | Time: 6-12 sessions over 3-6 weeks. 1,500 shocks/session at 0.09 mJ/mm², 5Hz. | Cost: $3,000-$6,000 total

Risks: Mild discomfort, bruising. Very safe overall.

Verdict: Legitimate for ERECTION improvement (solid randomized controlled trial data). NOT for size increase (no data whatsoever). Companies marketing shockwave for "size gains" are being misleading. If they claim size benefits, ask for the study — it doesn't exist.

Weight Loss (Lifestyle)

Evidence: Strong — Not "growth" — reveals buried shaft. But the functional and visible result is real.

Mechanism: Reduces suprapubic fat pad, exposing buried penile shaft. Also improves testosterone levels (adipose tissue aromatizes T to estrogen), endothelial function, and cardiovascular health. All of these improve erection quality.

Gains: Visible length: +1-3cm depending on weight loss. Erection quality: significantly improved. | Time: Months of diet/exercise (gradual). | Cost: Free (or cost of gym/diet)

Risks: None. Universally beneficial for health.

Verdict: Most impactful lifestyle change for overweight men. Simultaneously improves visible size, erection quality, testosterone, cardiovascular health, and self-confidence. If BMI >30, this should be step one before considering any device or procedure.

Supplements (L-arginine, Ginseng, etc.) (Supplement)

Evidence: None (for size) — May improve erection quality modestly. Will NEVER increase dimensions. "Male enhancement pills" for size are scams.

Mechanism: L-arginine: nitric oxide precursor (L-arg → NO via nitric oxide synthase). L-citrulline: converts to L-arginine (better oral bioavailability). Panax ginseng: ginsenosides promote NO release + adaptogenic. Yohimbine: alpha-2 antagonist (prescription in some countries).

Gains: Improved erections: possible (modest, less than PDE5i). Size: NONE. | Time: Daily supplementation for 8-12 weeks. | Cost: $10-$50/month

Risks: Generally safe. L-arginine: GI upset, may interact with blood pressure meds and nitrates. Yohimbine: anxiety, tachycardia, hypertension (not OTC-safe for everyone).

Verdict: L-arginine/citrulline and Korean red ginseng have real (if modest) evidence for ERECTION improvement. They will NOT increase size. Any product claiming "male enhancement" or "growth" from a pill is a scam. The FTC and FDA have taken enforcement action against dozens of such companies.

Fat Injection / Dermal Grafts (Girth) (Surgery)

Evidence: Weak — High reabsorption rates, uneven results, poor long-term outcomes.

Mechanism: Autologous fat or dermal grafts injected/placed subcutaneously around penile shaft for girth enhancement.

Gains: Girth: +1-2cm initially, but 30-50% reabsorption. Often uneven. | Time: Surgery + recovery. May need revision. | Cost: $5,000-$15,000

Risks: Fat reabsorption (30-50%), asymmetry, lumps, infection, granulomas, donor site morbidity.

Verdict: Unpredictable results due to high fat reabsorption. HA fillers now preferred for temporary girth. PMMA (permanent) carries foreign body reaction risk. Not recommended by most urological guidelines.

Dangerous Methods (Silicone/Vaseline/Paraffin Injection) (DANGEROUS)

Evidence: N/A — DOCUMENTED CASES OF DEATH, AMPUTATION, AND PERMANENT DISFIGUREMENT.

Mechanism: Non-medical grade silicone, petroleum jelly, paraffin oil, or mineral oil injected subcutaneously. Causes severe foreign body granulomatous reaction.

Gains: Temporary disfiguring swelling followed by destruction. | Time: N/A | Cost: N/A

Risks: EXTREME: Foreign body granuloma, chronic infection, penile necrosis, gangrene, amputation, pulmonary embolism, DEATH. These are NOT theoretical risks — they are documented outcomes.

Verdict: NEVER. These materials cause permanent, disfiguring, potentially fatal damage. If someone offers this, run. Seek emergency medical care if already done.

DHT (Dihydrotestosterone) Topical Cream

Target: SIZE (micropenis only) | Status: Proven in children; ineffective in adults | Evidence: Strong (pediatric)

Mechanism: DHT binds androgen receptors in penile tissue with 5x potency of testosterone. Drives penile growth during critical developmental windows. Applied topically to penis 12.5-25mg/day.

Key Study: Randomized trial (PMC 2023): n=49, DHT group +2.37cm vs testosterone +1.82cm. Mean age 9.7 years. Also: 153% increase rate in first 4 weeks (n=22, 1993 study).

Limitation: Only works in prepubertal children with micropenis/hormonal deficiency. Adult PAIS case: no response. After normal puberty, penile androgen receptors are downregulated.

Testosterone (IM/Topical)

Target: SIZE (micropenis only) | Status: Proven in children; no adult size effect | Evidence: Strong (pediatric)

Mechanism: Testosterone enanthate 25-50mg IM q3-4 weeks x 3 months. Activates androgen receptors. In children: drives pubertal penile growth. In adults: improves libido and erection quality only.

Key Study: Topical T: +60% length, +52.9% girth in prepubertal micropenis. Minimal response post-puberty. Good response = 100% increase in length during initial treatment.

Limitation: Post-pubertal adults: zero size effect. Only affects libido, erection quality, muscle mass. The "T booster = bigger penis" claim is a myth for normal adults.

hCG (Human Chorionic Gonadotropin)

Target: SIZE (hypogonadism only) | Status: Used in hypogonadotropic hypogonadism | Evidence: Moderate

Mechanism: Stimulates Leydig cells to produce endogenous testosterone. Used when pituitary/hypothalamic dysfunction prevents natural testosterone production.

Key Study: Penile growth documented in IHH patients. Preferred over exogenous T when fertility preservation is desired.

Limitation: Only works when the issue is insufficient endogenous testosterone production. No effect in men with normal HPG axis.

PRP (Platelet-Rich Plasma) / P-Shot

Target: SIZE (claimed) + ED | Status: Failed placebo-controlled replication | Evidence: Weak

Mechanism: Autologous blood concentrate injected intracavernously. Claimed to release growth factors promoting tissue regeneration.

Key Study: Pilot (n=29): +0.8" length, +0.47" girth at 6mo (NO placebo control). US placebo-controlled replication: "did not differ significantly from placebo at any time point." Cleveland Clinic: "no good evidence."

Limitation: The one positive study was uncontrolled. When properly controlled, it failed. Despite this, clinics charge $1,500-3,000/session.

Stem Cell Therapy (MSC)

Target: ED (not size) | Status: Phase I-II clinical trials | Evidence: Moderate (ED only)

Mechanism: Mesenchymal stem cells (adipose or bone marrow derived) injected intracavernously. Paracrine effects: secretome promotes angiogenesis, smooth muscle regeneration, anti-fibrosis.

Key Study: 2025 meta-analysis: 6 studies, 75 patients total. Significant IIEF improvements at 6 months. NCT06605508 (2024): extracellular vesicle trial recruiting.

Limitation: Small studies, no large randomized controlled trials yet. NO trial has measured SIZE changes — only erectile function. Whether MSCs actually differentiate into cavernosal smooth muscle in humans is unknown.

hMaxi-K Gene Therapy (hSlo)

Target: ED | Status: Phase I complete; Phase II registered | Evidence: Weak (early)

Mechanism: Naked DNA plasmid encoding the hSlo gene (Maxi-K channel alpha subunit) injected intracavernously. Increases Maxi-K channel expression → enhanced smooth muscle relaxation → improved erection.

Key Study: Melman 2006 Phase I: 11 patients, single intracavernosal injection (500-7500μg). 2/11 had improved erections lasting 6 months. No adverse events. NCT02713789: Phase II double-blind placebo-controlled registered.

Limitation: Very early stage. Small Phase I. No size effect expected — mechanism is smooth muscle relaxation, not tissue growth. But represents a novel non-PDE5 approach.

Bremelanotide (PT-141/Vyleesi)

Target: Sexual desire + erection | Status: FDA-approved (female HSDD); off-label male use | Evidence: Moderate (male ED, off-label)

Mechanism: MC3R/MC4R agonist. Acts centrally in hypothalamus → dopamine release into reward/motivation centers. Generates DESIRE rather than facilitating physical response to existing desire.

Key Study: Male ED: 67% vs 33% placebo improved erections. Sildenafil-resistant: 62% vs 21% placebo. SC injection 45 min before activity. Max 8 doses/month.

Limitation: NOT for size increase. Nausea in 40%. BP increase (contraindicated in CVD/uncontrolled HTN). Acts on desire, not vasodilation.

Rho-Kinase Inhibitors (Fasudil, Y-27632)

Target: ED | Status: Preclinical only (no human ED trials) | Evidence: Strong preclinical; no human data

Mechanism: Block RhoA/ROCK pathway that MAINTAINS flaccid state (smooth muscle contraction). Removing the "brake" on erection. Opposite approach to PDE5i (which amplifies the "gas").

Key Study: Oral fasudil restored ED in diabetic rats (4 weeks). Topical Y-27632 caused erection in rats. Human tissue: EC50=2.2μM. ADDITIVE with PDE5i in human tissue from non-responders — potential combination therapy.

Limitation: No human clinical trials for ED yet. Systemic Rho-kinase inhibition has cardiovascular effects. Needs selective penile delivery.

Hydrogen Sulfide (H₂S) Donors

Target: ED | Status: Preclinical only | Evidence: Preclinical only

Mechanism: Third gasotransmitter (after NO and CO). H₂S relaxes corpus cavernosum via KATP and KCa channels. Synergistic with NO pathway. ACS6 = H₂S-donating sildenafil compound.

Key Study: NaHS relaxes human corpus cavernosum concentration-dependently. Na₂S intracavernosal injection increased ICP in rats dose-dependently. Combined H₂S+PDE5i showed positive effects in animal models.

Limitation: No human clinical trials. Delivery method and safety profile in humans unknown. But represents a genuinely novel therapeutic pathway.

Topical Nitroglycerin (MED2005)

Target: ED | Status: Phase II complete; mixed results | Evidence: Weak

Mechanism: Direct NO donor applied topically to glans. Bypasses endothelial dysfunction by providing exogenous NO directly.

Key Study: MED2005 Phase II: 0.2% GTN gel. IIEF-EF 17.1→19.6. 23.1% clinically relevant improvement. But: home placebo-controlled study showed no significant effect.

Limitation: Only effective in mild ED. Partner headache from transferred nitroglycerin. Contradictory results between lab and home settings.

Topical Minoxidil

Target: ED (not size) | Status: Failed in most trials | Evidence: None

Mechanism: KATP channel opener + vasodilator. Applied 2% solution topically to penis.

Key Study: One positive study in neurogenic patients. One negative study (19/21 patients: no improvement). Internet community claims for GROWTH have ZERO clinical support.

Limitation: Does not work for ED in most patients. No evidence whatsoever for size increase despite widespread internet claims.